Relugolix and radiation therapy may be a safe, effective combination for treating prostate cancer

A high impact study led by Daniel Spratt, M.D., Vincent K. Smith Chair in Radiation Oncology at University Hospitals Seidman Cancer Center demonstrates the safety and efficacy of a novel oral hormone therapy, relugolix, in conjunction with radiation therapy for treating men with localized and advanced prostate cancer.

Reunion Neuroscience Announces Publication of Results from Early Preclinical Studies Demonstrating the Potential of Re104 for Development in Depressive Disorders | Psychedelic Invest

Reunion Neuroscience Inc. announced the publication of the results of preclinical studies in ACS Chemical Neuroscience that validate the decisions to pursue RE104, a proprietary,

May 24, 2024

Uveitis History Linked to Recurrence After COVID Vaccination

People with a history of uveitis were more likely to experience recurrences of the potentially dangerous eye inflammation after vaccination against COVID-19, a retrospective population-based

April 26, 2024

Semaglutide linked to increased risk of severe eye condition NAION in new study

Research shows semaglutide users face a significantly higher risk of developing non-arteritic anterior ischemic optic neuropathy (NAION) compared to users of other medications for diabetes

July 9, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.